Halsey Colby, Chugh Aman
Section of Cardiac Electrophysiology, Division of Cardiology, Cardiovascular Center, University of Michigan Hospitals, 1500 East Medical Center Drive, SPC 5853, Ann Arbor, MI 48109-5853, USA.
Section of Cardiac Electrophysiology, Division of Cardiology, Cardiovascular Center, University of Michigan Hospitals, 1500 East Medical Center Drive, SPC 5853, Ann Arbor, MI 48109-5853, USA.
Heart Fail Clin. 2016 Apr;12(2):193-203. doi: 10.1016/j.hfc.2015.08.016.
Treatment of patients with symptomatic atrial fibrillation (AF) with antiarrhythmic drug therapy in general improves their symptom scores and exercise tolerance; however, large randomized trials have failed to show a mortality benefit with a rhythm-control compared with a rate-control strategy. Catheter ablation in patients who have failed or not tolerated medical therapy has been shown to alleviate symptoms and improve quality of life. However, catheter ablation cannot undo the structural remodeling that contributed to the arrhythmia in the first place. Patients should be alerted to modifiable factors that may decrease the likelihood of unchecked structural remodeling and AF recurrence.
一般而言,采用抗心律失常药物治疗有症状性心房颤动(AF)患者可改善其症状评分和运动耐量;然而,大型随机试验未能表明与心率控制策略相比,节律控制具有死亡率获益。对于药物治疗无效或不耐受的患者,导管消融已被证明可缓解症状并改善生活质量。然而,导管消融无法消除最初导致心律失常的结构重塑。应提醒患者注意一些可改变的因素,这些因素可能会降低不受控制的结构重塑和房颤复发的可能性。